TY  - JOUR
AU  - Gerhäuser, Clarissa
AU  - Favero, Francesco
AU  - Risch, Thomas
AU  - Simon, Ronald
AU  - Feuerbach, Lars
AU  - Assenov, Yassen
AU  - Heckmann, Doreen
AU  - Sidiropoulos, Nikos
AU  - Waszak, Sebastian M
AU  - Hübschmann, Daniel
AU  - Urbanucci, Alfonso
AU  - Girma, Etsehiwot G
AU  - Kuryshev, Vladimir
AU  - Klimczak, Leszek J
AU  - Saini, Natalie
AU  - Stütz, Adrian M
AU  - Weichenhan, Dieter
AU  - Böttcher, Lisa-Marie
AU  - Toth, Reka
AU  - Hendriksen, Josephine D
AU  - Koop, Christina
AU  - Lutsik, Pavlo
AU  - Matzk, Sören
AU  - Warnatz, Hans-Jörg
AU  - Amstislavskiy, Vyacheslav
AU  - Feuerstein, Clarissa
AU  - Raeder, Benjamin
AU  - Bogatyrova, Olga
AU  - Schmitz, Eva-Maria
AU  - Hube-Magg, Claudia
AU  - Kluth, Martina
AU  - Huland, Hartwig
AU  - Graefen, Markus
AU  - Lawerenz, Christian
AU  - Henry, Gervaise H
AU  - Yamaguchi, Takafumi N
AU  - Malewska, Alicia
AU  - Meiners, Jan
AU  - Schilling, Daniela
AU  - Reisinger, Eva-Maria
AU  - Eils, Roland
AU  - Schlesner, Matthias
AU  - Strand, Douglas W
AU  - Bristow, Robert G
AU  - Boutros, Paul C
AU  - von Kalle, Christof
AU  - Gordenin, Dmitry
AU  - Sültmann, Holger
AU  - Brors, Benedikt
AU  - Sauter, Guido
AU  - Plass, Christoph
AU  - Yaspo, Marie-Laure
AU  - Korbel, Jan O
AU  - Schlomm, Thorsten
AU  - Weischenfeldt, Joachim
TI  - Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.
JO  - Cancer cell
VL  - 34
IS  - 6
SN  - 1535-6108
CY  - New York, NY
PB  - Elsevier
M1  - DKFZ-2018-02264
SP  - 996 - 1011.e8
PY  - 2018
AB  - Identifying the earliest somatic changes in prostate cancer can give important insights into tumor evolution and aids in stratifying high- from low-risk disease. We integrated whole genome, transcriptome and methylome analysis of early-onset prostate cancers (diagnosis ≤55 years). Characterization across 292 prostate cancer genomes revealed age-related genomic alterations and a clock-like enzymatic-driven mutational process contributing to the earliest mutations in prostate cancer patients. Our integrative analysis identified four molecular subgroups, including a particularly aggressive subgroup with recurrent duplications associated with increased expression of ESRP1, which we validate in 12,000 tissue microarray tumors. Finally, we combined the patterns of molecular co-occurrence and risk-based subgroup information to deconvolve the molecular and clinical trajectories of prostate cancer from single patient samples.
LB  - PUB:(DE-HGF)16
C6  - pmid:30537516
DO  - DOI:10.1016/j.ccell.2018.10.016
UR  - https://inrepo02.dkfz.de/record/142034
ER  -